Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mod Pathol. 2021 Aug;34(8):1495-1506. doi: 10.1038/s41379-021-00796-9. Epub 2021 Apr 6.
Lobular carcinoma in situ (LCIS) is currently classified as classic (CLCIS), florid (FLCIS), and pleomorphic (PLCIS). Given the rarity of FLCIS and PLCIS, information on their clinico-pathologic features and biologic potential remains limited. We evaluated the upgrade rates at excision of FLCIS and PLCIS diagnosed on inhouse core needle biopsy (CNB) and their clinical presentation and follow-up. Over a period of 11 and a half years, there were a total of 36 inhouse CNBs with pure PLCIS (n = 8), FLCIS (n = 24), or LCIS with pleomorphic features (LCIS-PF) (n = 4). The upgrade rates to invasive carcinoma or ductal carcinoma in situ (DCIS) were 25% for PLCIS (2/8), 17% for FLCIS (4/24), and 0% for LCIS-PF (0/4). The overall upgrade rate of PLCIS and FLCIS combined was 19% (6/32). All but one case (not upgraded at excision) were radiologic-pathologic concordant. Apocrine features, previously reported only in PLCIS, were also noted in FLCIS. HER2 overexpression was seen in 13% of cases. This study highlights the more aggressive biologic features of PLCIS and FLCIS compared to CLCIS and supports surgical management for these lesions.
乳腺小叶原位癌(LCIS)目前分为经典型(CLCIS)、增生型(FLCIS)和多形型(PLCIS)。鉴于 FLCIS 和 PLCIS 较为罕见,其临床病理特征和生物学潜能的信息仍然有限。我们评估了在切除经院内核心针活检(CNB)诊断的 FLCIS 和 PLCIS 时的升级率,以及它们的临床表现和随访情况。在 11 年半的时间里,共有 36 例经院内 CNB 诊断为单纯 PLCIS(n=8)、FLCIS(n=24)或具有多形性特征的 LCIS(LCIS-PF)(n=4)。侵袭性癌或导管原位癌(DCIS)的升级率为 PLCIS 25%(2/8)、FLCIS 17%(4/24)和 LCIS-PF 0%(0/4)。PLCIS 和 FLCIS 的总升级率为 19%(6/32)。除了 1 例(切除时未升级)外,所有病例均为影像学-病理学一致。先前仅在 PLCIS 中报道的大汗腺特征也在 FLCIS 中发现。HER2 过表达见于 13%的病例。本研究强调了 PLCIS 和 FLCIS 比 CLCIS 具有更具侵袭性的生物学特征,并支持对这些病变进行手术治疗。